The study drug is a potential new treatment for osteoporosis.
This is a condition that causes the bones to become thin and weak, which increases the risk of broken bones. The study drug is a biosimilar of an already approved drug (in Europe and the US).
A biosimilar is an almost identical copy of an already approved drug that is manufactured by a different drug. Biosimilar medications are important because they give patients access to more brand options, provide more affordable alternatives, and reduce the risk of medicine shortages.
The trial has been approved by an independent ethics committee and eligible participants will be reimbursed for their time.
Call us on 1800 243 733 to discuss your eligibility today!